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Abstract
Background: European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE)
V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in
2016–2018. The main objective was to determine whether the 2016 Joint European Societies’ guidelines on cardiovas-
cular disease prevention in people at high cardiovascular risk have been implemented in clinical practice.
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Methods: The method used was a cross-sectional survey in 78 centres from 16 European countries. Patients without a
history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering
treatments were identified and interviewed 6 months after the start of medication.
Results: A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 11.6 years)
interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5%
obese (body mass index 30 kg/m2) and 63.8% centrally obese (waist circumference 88 cm for women, 102 cm for
men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg
in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol
target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%.
Conclusion: The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high
cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus,
the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology
programmes is substantial.
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Introduction
The main objectives of cardiovascular disease (CVD)
prevention are to reduce morbidity and mortality,
improve quality of life and increase life expectancy.1
The Joint European Societies (JES) guidelines on
CVD prevention have been regularly updated since
19941–6 and their implementation evaluated with five
cross-sectional surveys called EUROASPIRE
(European Action on Secondary and Primary
Prevention by Intervention to Reduce Events) from
1995–1996 to 2016–2018 through the European
Society of Cardiology (ESC) EURObservational
Research Programme (EORP).7–17
Primary prevention of atherosclerotic CVD remains
a major challenge. Observational studies and rando-
mised controlled trials verify that healthy lifestyles
and the control of arterial hypertension, dyslipidaemia
and diabetes prevent CVD events in people free from
such disease.18–25 The aim of the primary care arm of
EUROASPIRE V was to determine to what extent the
2016 JES guidelines on CVD prevention had been
implemented in clinical practice in people at high risk
of developing CVD.
Methods
Study design
The primary care arm of EUROASPIRE V was carried
out in 78 primary care centres in 16 countries (Bosnia
and Herzegovina, Bulgaria, Croatia, the Czech
Republic, Egypt, Greece, Kazakhstan, Kyrgyzstan,
Lithuania, Poland, Portugal, Romania, Russia,
Sweden, Ukraine and the United Kingdom) during
2017–2018. Within each country one or more areas
with a defined population were selected and a sample
of 2 general practices serving that population were
identified.
Study population
Men and women, 18–<80 years, free from any ath-
erosclerotic disease, who had been prescribed one or
more of the following: (a) blood pressure lowering
drugs and/or (b) lipid-lowering drugs and/or (c) glu-
cose-lowering (diet and/or oral drugs and/or insulin)
6 months to <2 years prior to the interview, were
retrospectively identified from the medical records.
The sampling principle was that patients treated for
hypertension, dyslipidaemia or diabetes had an
approximately equal chance of being included.
Patients on each of these treatments might have one
or more of the other drug therapies.
Data collection
Data collection was undertaken by trained research
staff, who reviewed the medical notes and invited the
patients to an interview and examination at least six
months after the prescription of the blood pressure,
lipid-lowering and diabetes therapy. Fasting (at least
12 h) blood samples were obtained at the same time.
Smoking was defined as self-reported smoking, and/
or a breath carbon monoxide exceeding 10 ppm using a
Smokerlyzer (Bedfont Scientific, Model Microþ).
Height and weight were measured in light indoor
clothes without shoes using SECA scales 701 and
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measuring stick model 220 (SECA Medical
Measuring Systems and Scales, Birmingham, UK).
Overweight was defined as a body mass index (BMI)
25–<30 kg/m2 and obesity as BMI 30 kg/m2.
Waist circumference was measured using a metal
tape horizontally in the mid-axillary line midway
between the lowest rim of the rib cage and tip of the
hip bone with the patient standing. Abdominal
overweight was defined as a waist circumference of
80–<88 cm for women and 94–<102 cm for men
and central obesity as a waist circumference of
88 cm for women and 102 cm for men.
Blood pressure was measured twice on the right
upper arm in a sitting position with an automatic digi-
tal Omron Comfort M6 sphygmomanometers
(OMRON Corporation, Kyoto, Japan) and the mean
was used for the analyses. This sphygmomanometer has
a specially designed Intelli Wrap Cuff Technology to
give more accurate measurements as the unique pre-
formed Comfort cuff adjusts to suit a variety of arm
sizes and shapes. Raised blood pressure was defined as
systolic blood pressure (SBP) 140mm Hg and/or dia-
stolic blood pressure (DBP) 90mm Hg (140/85mm
Hg in patients with diabetes)
The physical activity target was defined by the fol-
lowing question ‘Do you take regular physical activity
of at least 30minutes duration on average five times
a week?’
Blood samples were analysed in the Central
Laboratory (Laboratory in the National Institute for
Health and Welfare, Helsinki, Finland), accredited by
the Finnish Accreditation Service and fulfilling require-
ments of the standard SFS-EN ISO/IEC 17025:2005.
During the course of the study the coefficient of vari-
ation (mean standard deviation (SD)) and systematic
error (mean SD) were 1.2% 0.1 and 0.0% 1.0 for
total cholesterol, 1.9% 0.5 and –0.1% 2.4 for high
density lipoprotein-cholesterol (HDL-C), 1.3% 0.2
and –1.8% 2.0 for triglycerides and 0.9% 0.1 and
–2.1% 3.4 for glycated haemoglobin (HbA1c),
respectively. Total cholesterol, HDL-C and triglycer-
ides were analysed in serum, and HbA1c in whole
blood by enzymatic methods for total cholesterol, tri-
glycerides and HbA1c and a homogenous method for
direct measurement of HDL-C (reagents from Abbott
Laboratories, Abbott Park, Illinois, USA). The level of
low density lipoprotein-cholesterol (LDL-C) was calcu-
lated by Friedewald’s formula when the triglycerides
level was <4.5mmol/l.26 Elevated LDL-C concentra-
tion was defined as 2.6mmol/l (100mg/dl).
Plasma glucose was analysed locally with a point-of-
care technique (Glucose 201RT, HemoCue,
Ängelholm, Sweden).27 Elevated fasting glucose
among patients with diabetes was defined as
6.0mmol/l (110mg/dl) and elevated HbA1c as
7.0% (International Federation of Clinical
Chemistry (IFCC) 53mmol/mol).
Data management
Data were submitted online to the data management
centre (EORP, European Heart House, Sophia
Antipolis, France). They were checked for complete-
ness, internal consistency and accuracy and stored
under the provisions of the National Data Protection
Regulations.
Statistical analyses
Descriptive statistics were used to estimate the preva-
lence rates of risk factors and medication use at inter-
view. Patients’ demographics, risk factor profiles and
use of medication were described according to
unweighted means, SDs and proportions. Prevalences
were compared between gender and age groups accord-
ing to Fisher’s exact test. All statistical analyses were
undertaken using SAS statistical software (release 9.4,
SAS Institute, Cary, North Carolina, USA) in the
Department of Public Health, Ghent University,
Belgium.
Ethical approval
National coordinators were responsible for obtaining
local ethics committee approvals. Written, informed
consent was obtained from each participant and
stored in the patient file.
Outcome measures
The main outcome measures were the proportions of
high CVD risk people achieving the lifestyle and risk
factor targets as defined in the 2016 JES guidelines on
CVD prevention: not smoking, healthy food choices
and being physically active; a BMI< 25 kg/m2; blood
pressure <140/90mm Hg (<140/85mm Hg in patients
with diabetes), LDL-C< 2.6mmol/l (<100mg/dl),
HbA1c as <7.0% (IFCC< 53mmol/mol) and appro-
priate use of cardioprotective drug therapies for
treatment of elevated blood pressure, lipids and
glucose.1
Results
Characteristics of the study population
A total of 3562 medical records were reviewed and 2759
patients attended the interview which, excluding patients
who died, moved away and had a change in medical
condition, corresponds to a participation rate of 70%.
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The distribution of study population attending interview
by country, age and gender is presented in Supplementary
Material Table 1. The mean (SD) age at interview was
59.0 (11.6) years and 57.6% were women.
Reasons for not being interviewed were: refusal to
attend (62%), no response to the invitation letter (36%)
and miscellaneous (2%). Women were significantly more
likely to attend the interview (74% vs 66% in men).
Study outcomes
Lifestyle. The prevalence of smoking, obesity and central
obesity are presented in Tables 1 and 2, Figure 1 and
Supplementary Material Table 2.
The overall prevalence of smoking was 18.1% (men
24.6%, women 13.3%), higher in patients <60 years. In
the past three years 18.6% of current smokers had not
been offered professional advice to quit and 58.5%
reported no intention to stop within the next six
months. Of the persistent smokers, 1.9% attended smok-
ing-cessation clinics and nicotine-replacement and vare-
nicline were used by 4.5% and 1.1% respectively.
Overall, 37.2% of patients (men 41.6%, women
33.9%) were overweight and 43.5% (men 41.7%,
women 44.9%) were obese. The prevalence of central
obesity was 63.8% (men 53.8%, women 71%). Of obese
patients, 18.6% had never been informed that they were
overweight, 37.6% were unaware of their weight target
Table 1. Patients’ lifestyle characteristics by age and gender.
Lifestyle characteristics
All
n¼ 2759
%
Gender Age
Men
n¼ 1170
%
Women
n¼ 1589
%
<60 years
n¼ 1344
%
60 years
n¼ 1415
%
Smoking 18.1 24.6 13.3a 24.9 11.7a
Current smokers not having been offered
professional advice to quit in past 3 years
18.6 15.5 23.0b 18.8 18.4
Current smokers not having attempted to quit smoking
in past 3 years
81.4 79.3 84.3 80.4 83.4
Current smokers not having the intention to quit within
the next 6 months
58.5 54.3 64.5b 55.9 64.1
Overweight and obesity 80.7 83.3 78.8a 79.6 81.8
Obesity 43.5 41.7 44.9 43.0 44.0
Central obesity 63.8 53.8 71.0a 60.4 67.0
Obese patients never been told to be overweight 18.6 17.1 19.6 18.9 18.2
Obese patients not having attempted actively to lose
weight in last month
49.2 51.4 47.7 47.2 51.0
Obese patients not seriously considering weight loss
in next 6 months
37.0 37.7 36.6 31.0 42.5a
Obese patients not being aware of their weight target 37.6 29.9 42.8a 39.7 35.7
Obese patients not having been advised to follow
dietary guidelines
36.8 36.5 37.1 34.3 39.1
Regular physical activity 30 minutes on average
5 times a week
36.4 39.8 33.8a 36.0 36.8
Vigorous physical activity for 20 minutes 3 or
more times a week
16.1 20.7 12.7a 18.8 13.6a
Performing planned physical activity to increase
physical fitness
31.6 35.5 28.6a 34.3 29.0a
Not performing planned physical activity and
no intention to do so in next 6 months
39.1 35.3 42.1a 30.9 47.2a
Not having received personal advice to do more
general everyday activities
55.2 52.6 57.1b 54.4 55.9
ACE : Angiotensin converting enzyme; BMI: body mass index; LLD: lipid-lowering drugs.
Smoking: self-reported smoking or >10 ppm carbon monoxide in breath; persistent smoking: self-reported smoking or >10 ppm carbon monoxide in
breath in patients reporting to have been smoking in the month prior to the index event; overweight: BMI 25–30 kg/m2; obesity: BMI 30 kg/m2; central
obesity: waist circumference 88 cm for women and 102 cm for men.
ap< 0.01; bp< 0.05.
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and 36.8% had not been advised to follow dietary
guidelines.
Regular physical activity (30min on average five
times/week) was undertaken by 36.4% of the patients
(men 39.8%, women 33.8%) while 39.1% did not per-
form any planned physical activity and had no inten-
tion to do so the next six months and 55.2% had not
received any advice to increase their physical activities
Blood pressure, lipids and diabetes. The management of
blood pressure, LDL-C and self-reported diabetes is
presented in Tables 3 and 4 and Supplementary
Material Tables 3 and 4.
Overall, 75.4% of patients were on antihypertensive
medication but 53% (men 56.6%, women 50.5%) had
blood pressure 140/90mm Hg (140/85mm Hg in
people with diabetes). A total of 84.2% on blood pres-
sure therapy were aware of their blood pressure level
and 69.2% knew their recommended target. The most
common medications were inhibitors of renin-angioten-
sin systems (ACE inhibitors/angiotensin receptor
blockers (ARBs); 78.9%), followed by beta-blockers
(37.9%), diuretics (35.6%) and calcium channel block-
ers (32%) with 42.2% on one, 34% on two, 17.7% on
three and 6.1% on 4 blood pressure lowering drugs.
Two-thirds of patients (64.9%) reported complete
adherence with the intake of their blood pressure low-
ering drugs. Furthermore, blood pressure was elevated
in 43.2% of patients not using antihypertensive medi-
cation. Of those being treated for hypertension 31.0%
Table 2. Reported lifestyle changes taken by patients to reduce their risk of heart disease within the last three years by age and
gender.
All
n¼ 2759
%
Gender Age
Men
n¼ 1170
%
Women
n¼ 1589
%
<60 years
n¼ 1344
%
60 years
n¼ 1415
%
Smokinga
Abstinence 15.1 17.2 12.2 16.3 12.6
Reduction 37.4 39.2 35.0 39.7 32.7
Smoking cessation clinic 1.9 1.5 2.5 2.2 1.3
Nicotine replacement therapy 4.5 4.7 4.1 4.4 4.6
Bupropion 0.6 0.7 0.5 0.3 1.3
Varenicline 1.1 1.5 0.5 0.9 1.3
In patients with BMI 30 kg/m2
Reduction of fat 71.8 69.3 73.5 74.2 69.7
Reduction of calories 62.0 60.8 62.9 65.7 58.7b
Participating in regular physical activity 39.3 44.1 36.1c 42.0 36.8
In patients using BP-lowering medication
Special dietd 53.9 51.9 55.2 51.0 56.3b
Reduction of salt 71.4 68.2 73.6c 69.8 72.7
Increased everyday physical activity 40.0 42.4 38.3 42.2 38.1
In patients using lipid-lowering medications
Special dietd 56.0 52.8 58.7 54.2 57.1
Reduction of fat 70.4 67.1 73.3b 69.7 70.9
More fruit and vegetables 76.0 74.8 77.0 74.7 76.8
More fish 60.1 60.7 59.5 58.6 61.0
Increased everyday physical activity 40.5 46.3 35.5c 39.9 40.9
In patients with diabetes
Reduction of fat 76.5 72.3 79.9c 78.6 75.1
More fruit and vegetables 77.5 77.5 77.4 76.7 78.0
Less sugar 80.8 81.3 80.5 84.3 78.5b
Less alcohol 51.3 53.1 49.9 54.7 49.2
Increased everyday physical activity 51.4 57.6 46.4c 49.7 52.5
BMI: body mass index; BP: blood pressure.
aChange during the last three years reported by smokers; bp< 0.05; cp< 0.01; dprescribed by a doctor or other health professional.
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were also on lipid-lowering medication and 50.4% had
an LDL-C 2.6mmol/l. Of those with hypertension
not on lipid-lowering medication 80.8% had an LDL-
C 2.6mmol/l.
Lipid-lowering medication was prescribed in 34.1%
and in this group 97.3%were on statins, 2.9% on fibrates
and 0.3% on other lipid-lowering drugs. Overall, 61.3%
reported 100% adherence with lipid-lowering drugs. Still,
53.1% of these patients (men 45.2%, women 59.9%) had
LDL-C 2.6mmol/l. Of these, 45.3%had been informed
of their cholesterol levels and only 29.9% were aware of
their target. Of patients on no lipid-lowering medication
81% had a LDL-C 2.6mmol/l (men 77.5%, women
83.3%). Of those being treated for dyslipidaemia,
70.8% were also on anti-hypertensive medication and
48.9% had a blood pressure above the recommended
target. Of dyslipidaemic patients not on anti-hypertensive
medication, 35.6%had a blood pressure above the target.
The prevalence of self-reported diabetes at interview
was 35.8% (men 37.2%, women 34.7%) and 34.8% of
people in this group had a HbA1c 7.0%. The major-
ity (79.2%) were on oral glucose-lowering drugs, 14.5%
on insulin and 57.2% on diet; 76.5% reported 100%
adherence with glucose-lowering drugs. In patients
with known diabetes, ACE inhibitors/ARBs were pre-
scribed in 56.0%, statins in 38.0% and both statins and
ACE/ARBs in 26.0%. Of those with diabetes, 69.8%
were on anti-hypertensive medication and 64.8% had a
blood pressure 140/85mm Hg. Of those with diabetes
not on anti-hypertensive medication, 55.1% had a
blood pressure140/85mmHg. A total of 39.5%
were on lipid-lowering medication but 41.9% had
an LDL-C 2.6mmol/l. Of those with diabetes
not on lipid-lowering medication, 74.5% had an
LDL-C 2.6mmol/l.
Discussion
Principal findings
The EUROASPIRE V survey in primary care clearly
demonstrates that a large majority of patients at high
CVD risk fail to achieve lifestyle, blood pressure, lipid
and glycaemic targets as defined in the 2016 JES guide-
lines on CVD prevention in clinical practice. A wide
gap still exists between the evidence-based guidelines
and everyday clinical practice.
A major concern is that nearly one-fifth of high
CVD risk patients were smokers with a prevalence
higher in men than women and in patients <50 years.
Moreover, two-fifths of current smokers did not intend
to quit smoking within the next six months. Despite the
evidence that stopping smoking is the most cost-effec-
tive strategy for prevention of CVD,1,28 only a small
minority of patients attended smoking cessation clinics
or were prescribed pharmacological support. There is a
failure of the primary care system to provide profes-
sional support for smoking cessation, including
prescription of evidence based medications like
varenicline and buproprion, and to address all aspects
of lifestyle including recommending physical activity,
especially in older groups. These poor outcomes on
smoking and physical activity management in such
high risk patients could be seen as professional
negligence.
A large majority of high CVD risk patients were
overweight or obese and nearly two-thirds were cen-
trally obese with the highest prevalence in women. Of
concern is that one-fifth of obese patients were never
told that they were overweight, and that more than a
third were unaware of their weight target and without
any dietary recommendations. Healthy diet and weight
reduction in overweight and obese patients are recom-
mended in order to reduce the blood pressure, lipids
and the risk of diabetes mellitus type 2.1,29 In this
survey, the majority of obese patients reported reducing
fat and calorie intake but only two-fifths participated in
regular physical activity.
There is a wealth of scientific evidence that control
of blood pressure, lipids and glucose can reduce the risk
of future CV events in high risk patients.21–25 However,
blood pressure management was poor with less than
half of patients on blood pressure lowering medication
achieving the guideline targets, slightly better in women
than men. Although a majority of patients were aware
of their blood pressure level and the target to be
achieved only 65% reported complete adherence with
their treatment. Of note is that more than two-fifths of
high CVD risk patients, because of dyslipidaemia and/
or diabetes, had elevated blood pressure without being
prescribed any antihypertensive therapy. The manage-
ment of LDL-C was surprisingly poor, with less than
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Figure 1. Prevalence (%) of smokinga by age and sex.b
aSelf-reported or >10 ppm CO in breath.
bSignificance of gender differences in smoking prevalences by age:
age <50 years: p¼ 0.0002; age 50–59 years: p¼ 0.0003; age
60–69 years: p< 0.0001; age 70 years: p¼ 0.45.
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half of patients on lipid-lowering medication achieving
the recommended target. Lipid control was better in
men than women. Surprisingly, less than half of
patients on lipid-lowering medication were aware of
their cholesterol levels and less than a third knew
their cholesterol target. However, over three-fifths of
patients reported 100% adherence with lipid-lowering
drugs. Similar to blood pressure, the majority of
patients selected as being at high risk, because of trea-
ted hypertension and/or diabetes, had elevated LDL-C
but without any prescription of lipid-lowering therapy.
More than two-fifths of patients with elevated LDL-C
had never been told they had high cholesterol. In
this survey, blood pressure was better controlled in
women than men and the reverse was true for LDL-
C, with similar observations reported in previous
EUROASPIRE III and IV surveys in primary care.14–16
There may be several explanations for the poor
blood pressure and lipid management, such as low-
dose prescriptions, not up-titrating doses to achieve
Table 3. Cardiovascular risk factor management by age and gender.
Risk factor
All
n¼ 2759
%
Gender Age
Men
n¼ 1170
%
Women
n¼ 1589
%
<60 years
n¼ 1344
%
60 years
n¼ 1415
%
BP 140/90 mm Hg (140/85 if diabetes) in patients
using antihypertensive drugs
53.0 56.6 50.5a 50.4 55.2b
BP 140/90 mm Hg (140/85 if diabetes) in patients not
using antihypertensive drugs
43.2 48.7 38.7b 36.6 52.5a
Awareness of BP level in patients using antihypertensive drugs 84.2 83.0 85.0 83.4 84.8
Awareness of BP target in patients using antihypertensive drugs 69.2 69.4 69.0 67.7 70.5
Reporting 100% adherence with BP lowering drugs 64.9 62.5 66.5 61.2 67.9a
If blood pressure raised, never been told by a doctor
to have high BP
13.0 15.3 11.0 13.8 12.3
BP 140/90 mm Hg (140/85 if diabetes) in obese patients
using antihypertensive drugs
60.5 61.5 59.8 61.4 59.7
B 140/90 mm Hg (140/85 if diabetes) in centrally obese
patients using antihypertensive drugs
57.0 60.1 55.4 56.7 57.3
BP 140/90 mm Hg (140/85 if diabetes) in obese patients
using lipid-lowering drugs
52.7 56.9 48.7 52.0 53.1
BP 140/90 mm Hg (140/85 if diabetes) in centrally obese
patients using lipid-lowering drugs
48.0 54.2 43.8b 42.5 51.2b
LDL-C 2.6 mmol/l in patients using lipid-lowering drugs 53.1 45.2 59.9a 62.2 47.3a
LDL-C 2.6 mmol/l in patients not using lipid-lowering drugs 81.0 77.5 83.3a 81.9 79.9
Awareness of total cholesterol level in patients using
lipid-lowering drugs
45.3 44.6 45.8 45.8 44.9
Awareness of total cholesterol target in patients using
lipid-lowering drugs
29.9 31.4 28.7 32.2 28.5
Reporting 100% adherence with lipid-lowering drugs 61.3 65.3 58.1b 54.3 66.1a
If LDL-C 2.6 mmol/l, never been told to have
high cholesterol
44.4 46.3 43.2 49.1 39.2a
Self-reported previous diabetes 35.8 37.2 34.7 29.2 42.0
In patients with self-reported diabetes, HbA1c 7.0% 34.8 32.5 36.6 37.0 33.4
Awareness of glucose level in patients with
self-reported diabetes
62.9 62.3 63.4 56.0 67.5a
Awareness of glucose target in patients with
self-reported diabetes
48.0 49.4 46.9 40.5 53.0a
Self-monitoring 72.4 72.3 72.5 66.6 76.2
Reporting 100% adherence with glucose-lowering drugs 76.5 75. 77.4 76.2 76.7
BP: blood pressure; LDL-C: low density lipoprotein-cholesterol.
ap< 0.01; bp< 0.05.
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targets, using monotherapy, poor patient adherence
and physician inertia to treat patients to targets accord-
ing to the most recent guidelines. Large clinical trials
demonstrate that most patients with hypertension can
achieve and sustain adequate blood pressure control,
however only with the use of two or more blood pres-
sure lowering drugs. In this survey, more than two-
fifths of patients on anti-hypertensive therapy were on
only one, while one-third were on two and just one-
fourth on three or more blood pressure lowering drugs.
According to the JES guidelines, people with diabetes
mellitus type 2 should be considered andmanaged as high
CVD risk and prescribed cardioprotective medications
including ACE inhibitors/ARBs and statins.1 However,
in this survey more than a third of patients with known
diabetes had HbA1c above the recommended target of
<7%. Overall, nearly three-fifths were on ACE
inhibitors/ARBs and only just over one-third on statins.
One important finding of this survey is that a large
majority of patients identified on the basis of being on
blood pressure and/or lipid-lowering medications and/
or having diabetes, were found to have more than one of
these risk factors. Counting the number of uncontrolled
cardiovascular risk factors (current smoking, elevated
blood pressure, elevated LDL-C or uncontrolled
diabetes), 38.7% had one, 40.1% had two, 10.8% had
three and 0.6% had four of them inadequately managed.
This underlines the importance of multifactorial cardio-
vascular risk factor management as the total CVD risk is
a consequence of the interaction of many risk factors
and modest increases of several risk factors can be
more harmful than a high level of a single risk factor.
Treating single risk factors in isolation is less effective
than screening for and managing all CVD risk factors,
and where one risk factor is detected it is essential to
screen for and manage all the others.
Comparison with other surveys
The results of EUROASPIRE V are in accordance with
other earlier surveys of primary prevention in Europe,
USA and other parts of the world.30–34 Most of them
focused on the control of a single risk factor while the
information on management of multiple CVD risk fac-
tors in patients at high CVD risk is limited. By com-
parison with the EURIKA study on 7641 patients from
12 European countries free of clinical CVD, and with at
least one major CVD risk factor, blood pressure and
LDL-C control in EUROASPIRE V was slightly
better.30 Among patients with treated hypertension,
Table 4. Use of blood pressure (BP) lowering, lipid-lowering and antidiabetic therapies.
Medication use (drug classes) % (n)
All (range between centres) Men Women
In people on BP lowering medication
Beta-blockers 37.9 (8.9 to 58.1) 33.4 41.1a
ACE inhibitors 51.7 (25.0 to 76.8) 52.8 50.8
ARBs 27.2 (8.7 to 49.1) 27.1 27.3
Calcium channel blockers 32.0 (12.6 to 57.1) 37.6 28.1a
Diuretics 35.6 (7.4 to 53.8) 35.0 36.0
Other BP lowering drugs 4.4 (0.0 to 12.1) 4.3 4.6
Number of BP lowering drugs:
1 BP lowering drug 42.2 (26.5 to 74.2) 41.6 42.6
2 BP lowering drugs 34.0 (21.0 to 41.8) 33.9 34.1
3 BP lowering drugs 17.7 (3.2 to 30.3) 17.7 17.8
4 BP lowering drugs 6.1 (0.0 to 16.3) 6.8 5.6
In people on lipid-lowering medication
Statins 97.4 (92.3 to 100) 97.3 97.4
Fibrates 2.9 (0.0 to 15.2) 3.9 2.0
Other LLD 0.3 (0.0 to 3.6) 0.2 0.4
Fixed-dose combination LLD 2.0 (0.0 to 8.4) 2.3 1.8
In people with self-reported diabetes
Diet 57.2 (21.6 to 95.1) 56.4 57.9
Oral antidiabetic drugs 79.2 (33.3 to 100) 77.4 80.6
Insulin 14.5 (0.0 to 35.2) 14.3 14.7
ARBs: angiotensin receptor blockers; LLD: lipid-lowering drugs; ACE: angiotensin converting enzyme.
ap< 0.01.
8 European Journal of Preventive Cardiology 0(00)
39% of patients in EURIKA achieved the blood pres-
sure target compared to 47% of patients in
EUROASPIRE V. Among treated patients with dysli-
pidaemia, 41% of patients in EURIKA attained an
LDL-C of <3mmol/l, compared to 47% achieving
LDL-C of <2.6mmol/l in EUROASPIRE V. In
another European study, 32% of high CVD risk
patients were smokers, 36% were obese, 49% had
blood pressure >140/90mmHg, 64% total cholesterol
5mmol/l and 14% a fasting glucose levels
>6.1mmol/l.31 Predictors of risk factor control were
medication adherence and health-related quality of
life. Being single and having a lower educational level
was associated with poorer risk factor control. The
International ChoLesterol management Practice Study
(ICLPS) investigated achievement of LDL-C targets in
patients at high or very high CVD risk receiving lipid-
modifying therapy in countries outside Western
Europe.32 The proportion of patients achieving
guideline-specified treatment targets was 44% for
LDL-C, 55% for blood pressure and 39% for diabetes.
Strengths and limitations
A major strength is that data were collected using face-
to-face interviews with standardised methods and
equipment, including central laboratory analyses,
rather than data from general practice medical records
where the risk factor recording is usually incomplete. A
limitation may be the way that patients were identified,
through prescription of blood pressure and/or lipid-
lowering and/or diabetes therapies, rather than screen-
ing to detect those at highest multifactorial CVD risk.
High CVD risk screening would have been labour-
intensive requiring assessment of a large number of
people to detect those at highest risk, while selecting
those already at high medical risk because they were
being treated with drug therapies was easier. The
majority of these selected patients had more than one
risk factor which puts them at high multifactorial risk
for CVD requiring a comprehensive approach to risk
factor reduction. The reason for choosing three geo-
graphical regions with a minimum of two general prac-
tices in each area in each country was to increase the
representativeness of the study.
Conclusions
Many European patients at high CVD risk have
unhealthy lifestyles including sedentary behaviour and
high prevalence of smoking, overweight, obesity and
central obesity. The control of blood pressure, lipids
and diabetes is poor with the majority of patients not
achieving guideline-recommended targets for CVD pre-
vention. There were considerable variations between
countries in lifestyle and risk factor management that
may be explained by the differences in drug prescribing
and local healthcare policies. The results demonstrate
that both patients and physicians pay insufficient atten-
tion to lifestyle risk factors which can unfavourably
impact on the control of blood pressure, lipids and dia-
betes. Thus, there is considerable potential to raise the
standards of preventive cardiology through modern
preventive cardiology programmes35 addressing all
aspects of lifestyle, multifactorial risk factor manage-
ment supported by comprehensive pharmacological
therapy in order to reduce the risk of future CVD.
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Konstantinos Tsioufis, GR; Dusko Vulic, BA; David
A. Wood, GB.
Coordinating centre
Agnieszka Adamska, GB; Sabina Adamska, GB;
Catriona Jennings, GB; Kornelia Kotseva, GB; David
A. Wood GB;
Diabetes centre
Viveca Gyberg, SE; Linda Mellbin, SE; Oliver Schnell,
DE; Lars Rydén, SE; Jaakko Tuomilehto, FI;
Statistical analysis centre
Dirk De Bacquer,BE; Guy De Backer, BE
Central laboratory
Laura Raman, FI; Jouko Sundvall, FI
Investigators
Bosnia & Herzegovina: Sarajevo: A. Begic, M. Dilic, Z.
Jatic , A. Keco, A. Osmanagic, N. Trifunovic, Banja
Luka: D. Vulic, Banja Luka: D. Djekic, Banja Luka:
M.Popovic, G.Tesanovic, Banja Luka: N.Todorovic,
Banja Luka: K.Stanetic, Banja Luka: V. Petrovic,
Banja Luka: N. Pilipovic-Broceta, Banja Luka: B.
Djukic, Banja Luka: B. Milankovic, Banja Luka: S.
Savic; Bulgaria: Sofia: B. Georgiev, N. Manova, N.
Gotcheva, A. Terziev, G. Vladimirov, Sofia: T.
Doychinova, M. Nikolova, Varna: S. Doncheva, S.
Ivanova, B. Kanazirev, S. Nikolaeva, D. Tonkova,
M. Vetkova; Croatia Zagreb: D. Milicic, Z. Reiner, J.
Samardzic; Zagreb: V. Cerovecki, I. Kermc, Zagreb: Z.
Ozvacic Adzic, Zagreb: G. Petricek, Zagreb: M.
Hanzevacki, Zagreb: K. Kranjcevic, Zagreb: I. Jukic-
Vojnic, Zagreb: I. Pecek, Zagreb:N. Buljan, Zagreb: V.
Bralic Lang; Czech Republic: Prague: J. Bruthans, R.
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